WallStreetZenWallStreetZen

NASDAQ: DMTK
Dermtech Inc Stock Forecast, Predictions & Price Target

Analyst price target for DMTK

Based on 2 analysts offering 12 month price targets for Dermtech Inc.
Min Forecast
$1.50+111.57%
Avg Forecast
$1.75+146.83%
Max Forecast
$2.00+182.09%

Should I buy or sell DMTK stock?

Based on 2 analysts offering ratings for Dermtech Inc.
Buy
Strong Buy
1 analysts 50%
Buy
0 analysts 0%
Hold
1 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their DMTK stock forecasts and price targets.

DMTK stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-07
lockedlocked$00.00+00.00%2024-03-05

1 of 1

Forecast return on equity

Is DMTK forecast to generate an efficient return?
Company
-105.97%
Industry
8.43%
Market
29.39%
DMTK's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is DMTK forecast to generate an efficient return on assets?
Company
-49.69%
Industry
3.26%
DMTK is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

DMTK revenue forecast

What is DMTK's revenue in the next 2 years based on estimates from 2 analysts?
Avg 1 year Forecast
$19.7M+28.46%
Avg 2 year Forecast
$24.2M+58.21%
DMTK's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

DMTK revenue growth forecast

How is DMTK forecast to perform vs Diagnostics & Research companies and vs the US market?
Company
28.46%
Industry
2.47%
Market
13.87%
DMTK's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
DMTK's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

DMTK vs Diagnostic & Research Stocks

TickerPricePrice TargetUp/downsideConsensus
DMTK$0.71$1.75+146.83%Buy
OCX$2.98$3.30+10.74%Buy
XGN$1.56N/AN/A
BIAF$2.08N/AN/A
CNTG$0.69N/AN/A

Dermtech Stock Forecast FAQ

Is Dermtech Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: DMTK) stock is to Buy DMTK stock.

Out of 2 analysts, 1 (50%) are recommending DMTK as a Strong Buy, 0 (0%) are recommending DMTK as a Buy, 1 (50%) are recommending DMTK as a Hold, 0 (0%) are recommending DMTK as a Sell, and 0 (0%) are recommending DMTK as a Strong Sell.

If you're new to stock investing, here's how to buy Dermtech stock.

What is DMTK's revenue growth forecast for 2024-2025?

(NASDAQ: DMTK) Dermtech's forecast annual revenue growth rate of 28.46% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 2.47%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.87%.

Dermtech's revenue in 2024 is $15,296,000.On average, 2 Wall Street analysts forecast DMTK's revenue for 2024 to be $680,350,655, with the lowest DMTK revenue forecast at $675,157,139, and the highest DMTK revenue forecast at $685,544,171.

In 2025, DMTK is forecast to generate $837,887,321 in revenue, with the lowest revenue forecast at $837,887,321 and the highest revenue forecast at $837,887,321.

What is DMTK's forecast return on assets (ROA) for 2024-2025?

(NASDAQ: DMTK) forecast ROA is -49.69%, which is lower than the forecast US Diagnostics & Research industry average of 3.26%.

What is DMTK's Price Target?

According to 2 Wall Street analysts that have issued a 1 year DMTK price target, the average DMTK price target is $1.75, with the highest DMTK stock price forecast at $2.00 and the lowest DMTK stock price forecast at $1.50.

On average, Wall Street analysts predict that Dermtech's share price could reach $1.75 by Mar 7, 2025. The average Dermtech stock price prediction forecasts a potential upside of 146.83% from the current DMTK share price of $0.71.

What is DMTK's forecast return on equity (ROE) for 2024-2025?

(NASDAQ: DMTK) forecast ROE is -105.97%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.